Characteristics of patients in the study cohort (n = 548) and those for whom medical records were available (n = 538) stratified by AIC cluster
| . | Cluster Assignment . | P value . | ||
|---|---|---|---|---|
| FL_aSHM, n (%) . | FL_STAT 6, n (%) . | FL_Com, n (%) . | ||
| Total (n = 548) | 58 (100.0) | 115 (100.0) | 375 (100.0) | |
| Male | 27 (46.6) | 55 (47.8) | 168 (44.8) | |
| Female | 31 (53.4) | 60 (52.2) | 207 (55.2) | .84 |
| Age at diagnosis, y | ||||
| Median (Interquartile range) | 66.5 (60.3-76.4) | 63.0 (54.3-71.6) | 63.6 (53.1-70.9) | .01 |
| <60 y | 14 (24.1) | 42 (36.5) | 146 (38.9) | |
| ≥60 y | 44 (75.9) | 73 (63.5) | 229 (61.1) | |
| Transformation to DLBCL | 8 (13.8) | 20 (17.4) | 68 (18.1) | |
| Deaths (before 01/01/2019) | 30 (51.7) | 45 (39.1) | 129 (34.4) | |
| 5-y survival, % | 60.0 | 76.5 | 80.5 | .10 |
| Medical records available (n = 538) | 57 (100.0) | 114 (100.0) | 367 (100.0) | |
| First-line management | ||||
| Chemotherapy | 27 (47.4) | 41 (36.0) | 155 (42.2) | |
| Radiotherapy only | 9 (15.8) | 32 (28.1) | 53 (14.4) | |
| Watch and Wait (W&W) | 19 (33.3) | 37 (32.4) | 156 (42.5) | |
| Induction rituximab | 2 (3.5) | 3 (2.6) | 0 | |
| Supportive/palliative care only | 0 (0.0) | 1 (0.9) | 3 (0.1) | .0015 |
| FLIPI | ||||
| Low | 16 (27.6) | 41 (35.7) | 105 (28.0) | |
| Intermediate | 10 (17.2) | 24 (20.9) | 86 (22.9) | |
| High | 21 (36.2) | 30 (26.1) | 123 (32.8) | .37 |
| Not known | 11 (19.0) | 20 (17.4) | 61 (16.3) | |
| Stage | ||||
| IA | 8 (13.8) | 22 (19.1) | 41 (10.9) | |
| IB | 0 | 0 | 5 (1.3) | |
| II | 7 (12.1) | 20 (17.4) | 39 (10.4) | |
| III | 18 (31.0) | 20 (17.4) | 63 (16.8) | |
| IV | 19 (32.8) | 39 (33.9) | 173 (46.1) | .01 |
| Not fully staged | 6 (10.3) | 14 (12.2) | 54 (14.4) | |
| B-symptoms | ||||
| No | 45 (77.6) | 91 (79.1) | 270 (72.0) | |
| Yes | 9 (15.5) | 23 (20.0) | 90 (24.0) | .28 |
| Not known | 4 (6.9) | 1 (0.9) | 15 (4.0) | |
| Performance status (ECOG) | ||||
| 0-1 | 49 (84.5) | 102 (88.7) | 342 (91.2) | |
| 2-4 | 7 (12.1) | 12 (10.4) | 22 (5.9) | .10 |
| Not known | 2 (3.4) | 1 (0.9) | 11 (2.9) | |
| Extranodal FL | ||||
| Yes | 0 (0) | 1 (0.9) | 9 (2.5) | |
| BCL2 rearrangement | ||||
| Measured | 25 (100) | 32 (100) | 114 (100) | |
| No | 4 (16.0) | 7 (21.9) | 13 (11.4) | |
| Yes | 21 (84.0) | 25 (78.1) | 101 (88.6) | .31 |
| BCL6 rearrangement | ||||
| Measured | 13 (100) | 16 (100) | 42 (100) | |
| No | 10 (76.9) | 13 (81.3) | 23 (54.8) | |
| Yes | 3 (23.1) | 3 (18.7) | 19 (45.2) | .10 |
| . | Cluster Assignment . | P value . | ||
|---|---|---|---|---|
| FL_aSHM, n (%) . | FL_STAT 6, n (%) . | FL_Com, n (%) . | ||
| Total (n = 548) | 58 (100.0) | 115 (100.0) | 375 (100.0) | |
| Male | 27 (46.6) | 55 (47.8) | 168 (44.8) | |
| Female | 31 (53.4) | 60 (52.2) | 207 (55.2) | .84 |
| Age at diagnosis, y | ||||
| Median (Interquartile range) | 66.5 (60.3-76.4) | 63.0 (54.3-71.6) | 63.6 (53.1-70.9) | .01 |
| <60 y | 14 (24.1) | 42 (36.5) | 146 (38.9) | |
| ≥60 y | 44 (75.9) | 73 (63.5) | 229 (61.1) | |
| Transformation to DLBCL | 8 (13.8) | 20 (17.4) | 68 (18.1) | |
| Deaths (before 01/01/2019) | 30 (51.7) | 45 (39.1) | 129 (34.4) | |
| 5-y survival, % | 60.0 | 76.5 | 80.5 | .10 |
| Medical records available (n = 538) | 57 (100.0) | 114 (100.0) | 367 (100.0) | |
| First-line management | ||||
| Chemotherapy | 27 (47.4) | 41 (36.0) | 155 (42.2) | |
| Radiotherapy only | 9 (15.8) | 32 (28.1) | 53 (14.4) | |
| Watch and Wait (W&W) | 19 (33.3) | 37 (32.4) | 156 (42.5) | |
| Induction rituximab | 2 (3.5) | 3 (2.6) | 0 | |
| Supportive/palliative care only | 0 (0.0) | 1 (0.9) | 3 (0.1) | .0015 |
| FLIPI | ||||
| Low | 16 (27.6) | 41 (35.7) | 105 (28.0) | |
| Intermediate | 10 (17.2) | 24 (20.9) | 86 (22.9) | |
| High | 21 (36.2) | 30 (26.1) | 123 (32.8) | .37 |
| Not known | 11 (19.0) | 20 (17.4) | 61 (16.3) | |
| Stage | ||||
| IA | 8 (13.8) | 22 (19.1) | 41 (10.9) | |
| IB | 0 | 0 | 5 (1.3) | |
| II | 7 (12.1) | 20 (17.4) | 39 (10.4) | |
| III | 18 (31.0) | 20 (17.4) | 63 (16.8) | |
| IV | 19 (32.8) | 39 (33.9) | 173 (46.1) | .01 |
| Not fully staged | 6 (10.3) | 14 (12.2) | 54 (14.4) | |
| B-symptoms | ||||
| No | 45 (77.6) | 91 (79.1) | 270 (72.0) | |
| Yes | 9 (15.5) | 23 (20.0) | 90 (24.0) | .28 |
| Not known | 4 (6.9) | 1 (0.9) | 15 (4.0) | |
| Performance status (ECOG) | ||||
| 0-1 | 49 (84.5) | 102 (88.7) | 342 (91.2) | |
| 2-4 | 7 (12.1) | 12 (10.4) | 22 (5.9) | .10 |
| Not known | 2 (3.4) | 1 (0.9) | 11 (2.9) | |
| Extranodal FL | ||||
| Yes | 0 (0) | 1 (0.9) | 9 (2.5) | |
| BCL2 rearrangement | ||||
| Measured | 25 (100) | 32 (100) | 114 (100) | |
| No | 4 (16.0) | 7 (21.9) | 13 (11.4) | |
| Yes | 21 (84.0) | 25 (78.1) | 101 (88.6) | .31 |
| BCL6 rearrangement | ||||
| Measured | 13 (100) | 16 (100) | 42 (100) | |
| No | 10 (76.9) | 13 (81.3) | 23 (54.8) | |
| Yes | 3 (23.1) | 3 (18.7) | 19 (45.2) | .10 |
ECOG, European Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index.